SOURCE: CNS Response

CNS Response

September 17, 2010 10:30 ET

CNS Response CEO George Carpenter to Present at the Fifth Annual JMP Securities Healthcare Industry Conference

ALISO VIEJO, CA--(Marketwire - September 17, 2010) -  CNS Response (OTCBB: CNSO) today announced that CEO George Carpenter will be presenting at JMP Securities Fifth Annual Healthcare Industry Conference to be held Monday, September 27, through Tuesday, September 28, at the New York Palace Hotel in New York, NY. This institutional investor forum will feature more than 100 leading publicly traded and privately held companies in the areas of biotechnology, medical devices and healthcare services.

Mr. Carpenter's presentation is scheduled for Tuesday, September 28, at 4:00 p.m. Institutional investors wishing to schedule a one-on-one meeting with Mr. Carpenter may do so by contacting JMP Securities' Kelly Weigel at KWeigel@LJFevents.com.

To access the live webcast of the presentation, go to http://www.wsw.com/webcast/jmp11/cnso.ob/. Please connect to the website at least five minutes prior to the presentation to allow time for registration. An archived replay will be available for 90 days beginning 24 hours after the live presentation. To view, visit the Investor Relations section of the CNS Response website at http://www.cnsresponse.com and click on http://www.wsw.com/webcast/jmp11/cnso.ob/.

About CNS Response
Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.

Referenced-EEG was developed by physicians to provide objective, personalized, statistical data on patient neurophysiology. In clinical trials, physicians using rEEG® data have consistently achieved superior clinical results compared to physicians using trial and error pharmacotherapy.

The Company recently announced publication of results from its most recent clinical trial in The Journal of Psychiatric Research, in which physicians using Referenced-EEG (rEEG®) had success rates reaching 65 percent for patients with treatment-resistant depression.

To read more about the benefits this patented technology provides physicians, patients and insurers, please visit the CNS Response website, www.cnsresponse.com.

Contact Information

  • Investor and Media Relations:
    Marty Tullio
    Managing Partner
    McCloud Communications, LLC
    949.553.9748
    Email Contact